BPC-157 TB-500 is a two-component research blend, drawn to scale across its angiogenesis and tissue-repair studies.

The two components on one sheet

BPC-157 TB-500 is not one molecule. It is a research-community pairing of two distinct synthetic peptides, sold and discussed under the name Wolverine. Read it as an assembly drawing: two dimensioned components on a single sheet, each with its own callout block, joined by a leader line that is honestly dashed.

Component one is BPC-157 (Body Protection Compound 157), a 15-amino-acid pentadecapeptide, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), molecular weight ~1419.5 Da, derived from a protein found in human gastric juice. Its role in the assembly is the local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 and activates the VEGFR2-Akt-eNOS pathway ^[2].

Component two is TB-500, a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, molecular weight ~889.0 Da, corresponding to residues 17-23 — the actin-binding region — of the 43-residue protein Thymosin Beta-4. Its role is the cytoskeletal signal: the LKKTETQ motif binds monomeric G-actin and regulates the actin dynamics that drive cell migration ^[3]. Worth flagging at the outset: most of the efficacy data filed under the name TB-500 was actually generated with full-length Thymosin Beta-4, a larger molecule than the heptapeptide in the vial — a gap this digest keeps visible rather than smoothing over ^[7].

This page sets the two components side by side, and the rest of the site follows that drawing. The Wolverine blend research summary details the measured findings; the BPC-157 and TB-500 angiogenesis research routes the vascular thread that is this digest's main lens; the BPC-157 TB-500 dosage in the literature keeps the research-context dose figures; and the Wolverine legal status and 503A compounding page keeps the FDA, 503A, and WADA record. For the short answers, see the frequently asked questions about the blend.

BPC-157 and TB-500: What the Wolverine Blend Pairs

The pairing of BPC-157 and TB-500 is a complementary-mechanism rationale. BPC-157 supplies a local, vessel-facing signal; TB-500 supplies an intracellular, cytoskeleton-facing signal. The two are described as acting through non-overlapping pathways, which is the basis of the marketed synergy claim.

The measured halves are real and separately characterized. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures, and reversed tendocyte growth inhibition into stimulation in vitro ^[1]. Thymosin Beta-4 — TB-500's parent protein — promotes cell migration, reduces scar-forming myofibroblasts, and drives angiogenesis ^[4].

The joint is the part that is not measured. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two peptides administered together. On the drawing, the two component edges are solid; the synergy leader between them is dashed.

BPC-157 with TB-500: The Combination Rationale {#bpc-157-with-tb-500}

BPC-157 with TB-500 is paired on the theory that a pro-angiogenic, cytoprotective component plus an actin-sequestration, pro-migration component would cover more of the repair cascade than either alone. BPC-157's VEGFR2-Akt-eNOS angiogenesis ^[2] and Thymosin Beta-4's migration and angiogenic activity ^[4] are the two legs. The combined effect remains a theoretical extrapolation: no controlled head-to-head or combination study has tested it ^[8].

BPC-157 TB-500 Stack (Wolverine) {#bpc-157-tb-500-stack}

The BPC-157 TB-500 stack is the same pairing under the community term stack. Commercial Wolverine vials are often labeled with a combined per-vial mass — for example 10 mg BPC-157 with 10 mg TB-500 — but no standardized composition or ratio is clinically validated. The stack inherits each component's evidence and each component's gaps.

What Is the Wolverine Peptide Blend?

The wolverine peptide blend is a research-community name for the two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair stack. It is not a single chemical entity and not an approved product, and no standardized composition or ratio is clinically validated.

What is BPC-157 and TB-500? {#what-is-bpc-157-and-tb-500}

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to residues 17-23 of Thymosin Beta-4 ^[3]. The Wolverine blend pairs the two. Neither is an FDA-approved drug.

What is the Wolverine peptide blend? {#what-is-the-wolverine-peptide-blend}

A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair stack. It is not a single chemical entity or an approved product, and no standardized composition or ratio is clinically validated. The consolidated Thymosin Beta-4 literature is one of its two evidence sources ^[4].

What is the difference between BPC-157 and TB-500? {#difference-bpc-157-tb-500}

BPC-157 is a 15-amino-acid pentadecapeptide (~1419.5 Da) from a human gastric-juice protein, acting on VEGFR2-Akt-eNOS angiogenic pathways ^[2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration ^[3]. They differ in size, source, and mechanism.

What is the blend used for in research? {#blend-used-for-in-research}

In animal models the two constituents are studied separately for tissue repair: BPC-157 for tendon, ligament, and muscle healing ^[1]; TB-500 / Thymosin Beta-4 for cell migration, wound re-epithelialization, and angiogenesis ^[4]. The combination itself has no controlled study ^[8].

Why are BPC-157 and TB-500 combined? {#why-are-bpc-157-and-tb-500-combined}

The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) ^[2] while TB-500 supplies an intracellular actin-sequestration signal driving cell migration ^[3]. The synergy is a theoretical extrapolation from two non-overlapping mechanisms, not a finding from a controlled combination study ^[8].

BPC 157 TB 500 (Unhyphenated)

BPC 157 TB 500 is the unhyphenated surface form of the same two-component blend. The chemistry does not change with the punctuation: BPC-157 remains the ~1419.5 Da pentadecapeptide and TB-500 remains the ~889.0 Da Ac-LKKTETQ heptapeptide. Both are supplied as lyophilized powders for research use, and both are prohibited by the World Anti-Doping Agency.

Wolverine Injection: Routes Studied in Research {#wolverine-injection}

Wolverine injection refers to the predominant research-community routes for the blend — subcutaneous and intramuscular. These routes are not drawn from controlled human efficacy trials. The underlying rodent efficacy studies for both peptides predominantly used the intraperitoneal route ^[1]; human single-agent reference points for full-length Thymosin Beta-4 used the intravenous route. The injection routes the community uses sit ahead of the human combination evidence, which does not exist ^[9].